Zydus gets USFDA approval for Levothyroxine Sodium for Injection

Zydus Lifesciences Limited on Tuesday has received final approval from the United States Food and Drug Administration (USFDA) for Levothyroxine Sodium for Injection 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial.

Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma, the company informed to the stock exchange.

Further, the drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).

The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04, the company said.

On Tuesday, at around 10:30 AM, Zydus Lifesciences was trading at Rs482.10 per share lower by 0.04% on the BSE.